Table 4.
List of currently approved erythropoietin biosimilars
| Region | Active substance (laboratory code) | Brand name (pharmaceutical company) | Indications in oncology | Approval date |
|---|---|---|---|---|
| Europe | Epoetin alfa (HX575) | Binocrit (Sandoz) | Treatment of anemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g., cardiovascular status, pre-existing anemia at the start of chemotherapy) | 28/08/2007 |
| Abseamed (Medice Arzneimittel) | 28/08/2007 | |||
| Epoetin alfa Hexal (Hexal) | 28/08/2007 | |||
| Epoetin zeta (SB309) | Retacrit (Hospira) | 18/12/2007 | ||
| Silapo (Stada Arzneimittel) | 18/12/2007 | |||
| Australia | Epoetin lambda | Aczicrit (Sandoz/Novartis) | Treatment of anemia in patients with non-myeloid malignancies where anemia develops as a result of concomitantly administered chemotherapy and where blood transfusion is not considered appropriate | 27/01/2010 |
| Grandicrit (Sandoz/Novartis) | 27/01/2010 | |||
| Novicrit (Sandoz/Novartis) | 27/01/2010 | |||
| New Zealand | Epoetin alpha (HX575) | Binocrit (Novartis) | Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy | 27/02/2013 |